Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9382586 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1LMNATP53MLYCD | |
| SCHEMBL1313198 | 0.91 | CYP1A2 (0.42) | CYP2C19CYP1A2CYP2C9MMP13 | |
| SCHEMBL7447969 | 0.91 | CYP1A2 (0.42) | CYP2C19CYP1A2CYP2C9MMP13 | |
| Cysteine SCHEMBL29016388 | 0.87 | SLC7A5 (0.42) | SMN1; SMN2ALDH1A1LMNATP53PRSS1 | |
| SCHEMBL8364820 | 0.86 | MT-CO2 (0.45) | SMN1; SMN2LMNATSHRTDP1MEN1 | |
| SCHEMBL1208677 | 0.86 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1LMNAPRSS1CTSG | |
| SCHEMBL10521312 | 0.86 | NR1H2 (0.34) | ALDH1A1LMNATP53PRSS1CTSG | |
| SCHEMBL2276227 | 0.86 | MT-CO2 (0.45) | SMN1; SMN2LMNATSHRTDP1MEN1 | |
| SCHEMBL3362092 | 0.86 | F2 (0.38) | ALDH1A1LMNAKMT2A | |
| SCHEMBL5846260 | 0.86 | KMT2A (0.40) | LMNAMEN1KMT2ANPSR1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024226691-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-10322103-B2 | Compositions for prevention/prophylactic treatment of poison ivy dermatitis | UNIVERSITY OF MISSISSIPPI (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180078520-A1 | COMPOSITIONS FOR PREVENTION/PROPHYLACTIC TREATMENT OF POISON IVY DERMATITIS | UNIVERSITY OF MISSISSIPPI | 2018-03-22 | — | — | US | disclosed |
| US-9408822-B2 | Compositions for prevention/prophylactic treatment of poison ivy dermatitis | THE UNIVERSITY OF MISSISSIPPI (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150202176-A1 | Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis | THE UNIVERSITY OF MISSISSIPPI | 2015-07-23 | — | — | US | disclosed |
| US-9029417-B2 | Compositions for prevention/prophylactic treatment of poison ivy dermatitis | THE UNIVERSITY OF MISSISSIPPI (US) | 2015-05-12 | — | — | US | disclosed |
| US-8853204-B2 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the RSV fusion protein | ARROW THERAPEUTICS LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| EP-2707363-A1 | A PROCESS FOR THE PREPARATION OF BENZYL [(3AS,4R,6S,6AR)-6-HYDROXY-2,2- DIMETHYLTETRAHYDRO-3AH-CYCLOPENTA[D][1,3]DIOXOL]-4-YL]CARBAMATE AND INTERMEDIATES IN THE PROCESS | AstraZeneca AB (SE) | 2014-03-19 | — | — | EP | disclosed |
| US-20130303582-A1 | COMPOSITIONS FOR PREVENTION/PROPHYLACTIC TREATMENT OF POISON IVY DERMATITIS | THE UNIVERSITY OF MISSISSIPPI | 2013-11-14 | — | — | US | disclosed |
| EP-0346208-A1 | 4-Amino quinolines and naphthyridines, process for their preparation and their use as medicaments | ELF SANOFI (FR) | 1989-12-13 | — | — | EP | disclosed |
| US-4847248-A | 1,4-Benzodiazepines with 5- and 6-membered heterocyclic rings and their use as cholecystokinins and gastrin antagonists | MERCK & CO., INC. (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0135379-B1 | BASIC HEXA- AND HEPTA-PEPTIDE VASOPRESSIN ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-04-20 | — | — | EP | disclosed |
| US-4735941-A | 1,4-benzodiazepines with 5- and 6-membered heterocyclic rings, useful as gastrointestinal and CNS agents | MERCK & CO., INC. (US) | 1988-04-05 | — | — | US | disclosed |
| US-4543349-A | Basic heptapeptide vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1985-09-24 | — | — | US | disclosed |
| EP-0135379-A2 | Basic hexa- and hepta-peptide vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1985-03-27 | — | — | EP | disclosed |
| EP-0041286-B1 | LH-RH ANTAGONISTS | Schally, Andrew Victor (US) | 1984-08-15 | — | — | EP | disclosed |
| US-4371463-A | Enzyme-resistant opiate pentapeptides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1983-02-01 | — | — | US | disclosed |
| US-4071622-A | Treatment of a mammary or DMBA inducible tumor | ABBOTT LABORATORIES (US) | 1978-01-31 | — | — | US | disclosed |
| US-4034082-A | Method to prevent reproduction in warm-blooded female animals with nonapeptides | ABBOTT LABORATORIES (US) | 1977-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303582-A1 | COMPOSITIONS FOR PREVENTION/PROPHYLACTIC TREATMENT OF POISON IVY DERMATITIS | UGT1A3, IL33, ITCH | SMN1; SMN2 3131/4885ALDH1A1 1518/4885LMNA 1183/4885 |
| US-20150202176-A1 | Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis | UGT1A3, IL33, ITCH | SMN1; SMN2 3131/4885ALDH1A1 1518/4885LMNA 1183/4885 |
| US-20180078520-A1 | COMPOSITIONS FOR PREVENTION/PROPHYLACTIC TREATMENT OF POISON IVY DERMATITIS | UGT1A3, ITCH, UGT1A1 | SMN1; SMN2 3622/4885ALDH1A1 850/4885LMNA 2090/4885 |
| US-10322103-B2 | Compositions for prevention/prophylactic treatment of poison ivy dermatitis | UGT1A3, ITCH, UGT1A1 | SMN1; SMN2 3622/4885ALDH1A1 850/4885LMNA 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.